Shanghai Allink Biotherapeutics

Shanghai Allink Biotherapeutics, established in 2023 and based in Shanghai's Zhangjiang Hi-Tech Park, is a clinical-stage biotechnology firm focused on developing treatments for oncology and immunology. The company specializes in creating bispecific antibodies and antibody-drug conjugates (ADCs). Its business model centers on the research, development, and eventual commercialization of these novel therapeutics. Allink Biotherapeutics leverages its proprietary technology platforms to create next-generation treatments.

The company was founded by Dr. Hui Feng, who serves as CEO. Dr. Feng earned his Ph.D. in Molecular Pharmacology from Albert Einstein College of Medicine and has nearly two decades of experience in the biopharmaceutical industry. His background includes roles at Medimmune (an AstraZeneca subsidiary) and TopAlliance Biosciences. He notably led the development of Toripalimab, China's first PD-1 monoclonal antibody to receive overseas approval. The co-founders include Kehua Fan (COO), who has extensive experience in clinical development and external collaborations, and Dr. Li Li (Head of Research), who holds a Ph.D. from the Shanghai Institute of Materia Medica.

Allink Biotherapeutics' core focus is its pipeline of First-in-Class (FIC) and Best-in-Class (BIC) therapeutics. The company utilizes a proprietary bispecific antibody platform and a novel conjugation technology to produce bispecific ADCs (BsADCs). These are engineered for optimized drug-to-antibody ratios, improved hydrophilicity, and greater stability. The company's pipeline includes more than 10 candidates, with two lead assets, ALK201 and ALK202, having advanced to Phase I clinical trials in the United States, China, and Australia. These trials are assessing the safety, tolerability, and preliminary anti-tumor activity in patients with advanced solid tumors. In November 2024, the company secured $42 million in a Series A financing round led by Lanchi Ventures, with participation from investors such as Legend Capital, Yuanbio Venture Capital, and existing shareholders Gaorong Ventures and Med-Fine Capital. These funds are designated for advancing the clinical development of its lead candidates, enriching its pipeline, and expanding its global operations.

Keywords: antibody-drug conjugates, bispecific antibodies, oncology therapeutics, immunology, clinical-stage biotechnology, biopharmaceutical, cancer treatment, ADC technology, BsADC, Hui Feng, Toripalimab, ALK201, ALK202, Lanchi Ventures, targeted therapy, FIC therapeutics, BIC therapeutics, drug development, biopharma, monoclonal antibody